Financings In Brief: Vical
Vical: Gene therapy R&D firm files registration for secondary offering of 2.5 mil. share of common stock with SEC, San Diego-based Vical announces Aug. 15. All shares are beings sold by the company, with Goldman, Sachs and Cowen & Co. managing the offer. Proceeds will be used for R&D expenses, including preclinical testing and clinical trials...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth